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Abstract
Background and Aims—Pre-transplant renal failure is commonly reported to be a poor 
prognostic indicator affecting survival after liver transplantation (LT). However, whether the 
impact of renal failure on patient outcome varies according to the etiology of the underlying liver 
disease is largely unknown.
Methods—We investigated the association between renal failure at the time of LT and patient 
outcome in patients with alcoholic liver disease (ALD)(n=6,920), nonalcoholic steatohepatitis 
(NASH)(n=2,956) and hepatitis C (HCV) (n=14,922) using the United Network for Organ Sharing 
(UNOS) database between February 2002 and December 2013. A total of 24,798 transplant 
recipients were included.
Results—The presence of renal failure was more frequently seen in patients with ALD (23.95%) 
and NASH (23.27%) compared to patients with HCV (19.38%)(p<0.001). In multivariate analysis, 
renal failure was an independent predictor of poor survival. Renal failure showed detrimental 
effect on patient survival in the overall series (HR=1.466, p<0.0001). Importantly, the impact of 
renal failure was less marked in patients with ALD (HR=1.31, p<0.0001) than in patients with 
NASH (HR=1.73, p<0.0001) or HCV (HR=1.52, p<0.0001). Despite a higher Model for End-stage 
Liver Disease (MELD) score at the time of LT, ALD patients with renal failure had better long-
term prognosis than non-ALD patients.
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Conclusions—Renal failure at the time of LT conferred a lower patient and graft survival post-
LT. However, renal failure has less impact on the outcome of patients with ALD than that of 
patients with non-alcoholic liver disease after LT.
INTRODUCTION
Liver transplantation (LT) is the ideal therapy for patients with end-stage liver disease. 
Alcoholic liver disease (ALD) is one of the most common etiologies among patients 
receiving LT in the United States and Europe (1, 2). Long-term survival after transplantation 
in patients with ALD is similar to that in patients with non-alcoholic steatohepatitis (NASH) 
or patients with hepatitis C virus (HCV) infection (3, 4).
Patients with end-stage liver disease are predisposed to renal hypoperfusion, the most 
common etiology of acute kidney injury (AKI) in cirrhosis (5, 6). Renal hypoperfusion can 
result in hepatorenal syndrome (HRS) or acute tubular necrosis (5, 7). The prevalence of 
renal dysfunction in liver transplant recipients ranges between 17% and 95% (8, 9). Since 
the introduction of the Model for End Stage Liver Disease (MELD) scoring system for 
prioritization of LT recipient, a high percentage of patients receiving LT have renal 
impairment (10), which can be a critical factor for post-transplant survival (11).
In the setting of cirrhosis, AKI can be caused by either chronic structural kidney disease or 
functional renal failure, depending on the type of liver disease. For example, non-alcoholic 
fatty liver disease and metabolic syndrome are associated with chronic kidney disease 
(CKD)(12), while type II cryoglobulinemia is frequently seen in chronic HCV infection and 
can lead to membranoproliferative glomerulonephritis (13). In contrast, HRS is more 
common in ALD according to a pooled analysis that found alcohol-related cirrhosis as the 
underlying etiology in 57% of cases (5). In a recent study from our group, the main causes 
of AKI in patients with advanced ALD were HRS and renal failure associated with infection 
(14). Moreover, IgA1-containing circulating immune complexes can cause secondary IgA 
nephropathy in patients with ALD (15). The high possibility of renal non-recovery in CKD 
after LT leads to the assumption that renal dysfunction in patients with NASH or HCV is 
more likely to be irreversible. HRS involves functional deterioration in renal function, which 
is more likely to be reversible after LT (16, 17).
Scoring systems to predict the prognosis of renal dysfunction in patients undergoing LT are 
used sparingly. Furthermore, the precise indications of combined liver-kidney 
transplantations remain unclear. Northup et al found the renal non-recovery to be as high as 
32% among LT recipients who were on pre-LT renal replacement therapy and received LT 
alone (16). There is a clear need to identify the factors affecting the outcome of patients with 
renal failure before LT. We hypothesized that the etiology of underlying liver disease plays a 
role, which is particularly evident in the fact that renal failure has less impact on survival 
after LT in ALD patients despite a higher prevalence of renal failure in this cohort than in 
other liver diseases. This study was undertaken to test this hypothesis.
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PATIENTS AND METHODS
Patient Data collection
We used the United Network for Organ Sharing and Organ Procurement and Transplantation 
Network (UNOS/OPTN) database and included any adult patients who received a liver 
transplant in the United States from February 27, 2002 through December 2012. As for the 
etiologies of chronic liver disease among LT recipients, we included only those subjects with 
a diagnosis code of 4204, 4215 or 4216, which correspond to ALD (n=6,920), HCV 
(n=14,922), and NASH (n=2,956) respectively. We excluded patients with combined ALD 
and HCV (n=3,076). We included only subjects aged 18 years or older, who had no missing 
data on their status (died, still alive, lost to follow up, re-transplanted), with a total of 24,798 
adult patients. The Institutional Review Board at the University of North Carolina at Chapel 
Hill approved this study.
Definitions and parameter selection
We extracted data from the UNOS database including anthropometric (e.g. body mass 
index), socioeconomic (e.g. race), baseline characteristics (e.g. age, gender, presence of 
diabetes or cardiac disease, MELD score, ascites, encephalopathy, portal vein thrombosis 
etc.), surgery related parameters (e.g. living or cadaver donor, combined liver/kidney 
transplant, ABO mismatch, cold ischemic time etc.) and early or late complications (e.g. 
cardiovascular complications, rejection etc.). A detailed description of the parameters 
included in the study is depicted in supplementary Table 1. The UNOS database has limited 
information on long-term complications (e.g. cardiovascular events, development of 
malignancy, accurate cause of death), resulting in a significant proportion of missing data. 
Outcome parameters were patient survival and graft survival.
As reported elsewhere, renal failure was considered in patients with serum creatinine ≥2.5 
mg/dL or treated with dialysis at the time of listing for LT (18, 19). Renal recovery was 
defined as serum creatinine <1.5 mg/dL at six months after LT.
Statistical analysis
Univariate and multivariate Cox proportional hazards models were used to identify 
predictors for patient survival and graft survival. To test whether hazard ratios for a 
particular variable differed between etiologies, an interaction term for the variable of interest 
and the etiologies was used. Multivariate analysis included variables that were biologically 
relevant and/or associated significantly in the univariate analysis (p<0.05).
To find significant disease-specific parameters in patients with renal failure, all the available 
parameters were compared by etiology of liver disease (alcoholic vs. non-alcoholic). 
Pairwise comparisons via Chi-square tests were used to test for two-way associations 
between categorical variables. Kaplan-Meier curves were generated along with log-rank p-
values to compare curves, and proportional hazards models were run to generate hazard 
ratios. P-values less than 0.05 were considered statistically significant. Analyses were 
performed using SAS Version 9.3 (SAS Institute, Cary, NC).
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RESULTS
Prevalence of renal failure/dialysis in patients with ALD, NASH and hepatitis C undergoing 
LT
We first analyzed the prevalence of renal failure and dialysis before LT according to the 
underlying liver disease. Renal failure was present in 23.95%, 23.27%, and 19.38% of 
patients with ALD, NASH and HCV, respectively. Pairwise comparison of each group 
demonstrated that ALD (p<0.001) and NASH (p<0.001) have higher prevalence of renal 
failure than patients with HCV (Table 1).
Patients requiring dialysis at the time of LT were 14.99%, 13.27% and 11.27% of patients 
with ALD, NASH and HCV, respectively. Similar to results in renal failure, pairwise 
comparisons indicated that the patients with ALD (p<0.001) and NASH (p=0.0019) were 
more likely to require dialysis than those with HCV. The difference between ALD and 
NASH was minimal and probably clinically irrelevant, despite a statistical significance due 
to the large sample size (Table 1).
Multivariate Analysis of Parameters Predicting Patient Survival after LT
We next investigated the parameters predicting patient survival after LT. Overall, patient 
mortality and graft failure were observed in 6,915 and 8,252 cases, respectively, out of 
24,798 cases. Outcomes in each etiology have been depicted in Table 2. Multivariate Cox 
proportional hazards models were used to identify independent parameters of patient 
survival. This multivariate analysis showed renal failure to be an independent prognostic 
factor for patient survival after adjustment for other clinical and laboratory features that have 
conventionally been accepted as having prognostic value in patients receiving LT 
(HR=2.648, p=0.0067). Other independent parameters for patient survival include: female 
gender, black race, donor age, body mass index, renal recovery, MELD score, anti-hepatitis 
B core antibody, ventilator support and previous liver transplant (Table 3). Since renal 
impairment may affect MELD score, we analyzed the impact of renal failure across three 
MELD classes (MELD score <20, 20–30 and >30)(20) in terms of graft and patient survival. 
This analysis showed that renal failure before transplant has higher impact in terms of 
patient survival in patients with a MELD score between 20–30. Absence of renal recovery 
impacts patient survival across all MELD classes. Pre-transplant renal impairment does not 
impact graft survival, however, a lack of renal recovery after transplantation does impact 
graft survival across all three MELD classes. Detailed multivariate results are depicted in 
Supplementary Table 2 and 3.
Role of the etiologies of liver disease on the impact of renal failure on patient and graft 
survival
We next explored the impact of renal failure on survival and the effect of underlying cause of 
liver disease on this outcome. We excluded patients with previous LT from this analysis, 
since these patients are on immunosuppressive drugs, which is independently associated 
with renal impairment and may serve as a confounding factor. As expected, patients with 
renal failure at the time of LT showed poorer graft survival (Figure 1).
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We also assessed survival in each type of liver disease according to the presence or absence 
of renal failure. To explore the impact of renal failure on survival in each etiological group, 
we conducted pairwise comparison in each disease group. Importantly, the impact of renal 
failure was significantly less marked in patients with ALD than in patients with NASH or 
hepatitis C (Figure 2) (Table 4).
Differences in baseline characteristics in patients with renal failure with ALD compared to 
patients with NASH and hepatitis C
We also sought to identify potential explanations for the reduced impact of renal failure in 
patients with ALD. As expected, ALD patients with renal failure showed better patient and 
graft survival than patients without ALD (i.e., NASH and hepatitis C) with renal failure 
(Figure 3). In fact, the long-term survival of patients with ALD and renal failure was similar 
to patients without renal failure.
To identify factors contributing to the difference in impact of renal failure based on 
underlying liver disease, we compared clinical and laboratory parameters between ALD 
patients with renal failure and non-ALD patients with renal failure in the whole series. As 
shown in Table 5, ALD patients with renal failure had more frequent bacterial peritonitis, 
greater frequency of encephalopathy (higher than grade 3), higher MELD scores and 
received more frequent dialysis compared to non-ALD patients with renal failure. In 
contrast, non-ALD patients with renal failure had a higher frequency of female gender, black 
race, diabetes, malignancy other than hepatocellular carcinoma, positive anti-hepatitis B core 
antibody, older age, higher body mass index, higher serum creatinine and longer cold and 
warm ischemic time compared to those of ALD patients with renal failure. There were no 
differences between the two groups with respect to the frequency of combined liver-kidney 
transplant (1,655 patients in the total cohort underwent a combined transplantation), positive 
rate of hepatitis B surface antigen, ventilator support, portal vein thrombosis, ABO 
mismatching, whole liver transplant, acute rejection episode, renal recovery, renal failure as 
cause of death and cardiovascular cause of death. The presence of diabetes, which is 
associated with parenchymal renal disease, could partially explain the poor outcome of 
patients with renal failure of non-alcoholic etiology.
DISCUSSION
Development of renal failure in patients receiving LT is a critical event affecting survival. 
We investigated the prevalence of renal failure in patients undergoing LT and the impact of 
the etiology of underlying liver disease. Patients with ALD and NASH have higher 
prevalence of renal failure at the time of LT than patients with hepatitis C, and the presence 
of renal failure was independently associated with lower survival following LT. Importantly, 
patient survival differed significantly with etiology of liver disease in patients with renal 
failure receiving LT. Our study reinforces previous studies, suggesting that pre-transplant 
renal failure is particularly harmful in patients with NASH (12, 21).
We analyzed data from the UNOS database from 2002 to 2013 that included approximately 
25,000 adult LT recipients to evaluate the impact of renal failure on post-LT survival. The 
UNOS database has been used extensively in other studies (1, 3, 22). However, this database 
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lacks specific data that would allow an assessment of duration of renal failure, dialysis, and 
pre-existing CKD before LT. Furthermore, detailed patient level data to determine the cause 
of renal dysfunction, causes of death and cardiovascular complications is not readily 
available in the UNOS database. We should cautiously interpret the cause of death 
considering the follow-up period of patients after LT. Cardiovascular complications are 
generally late events appearing 10–15 years after LT as a relevant cause of death. Thus a 
considerable proportion of LT patients lacked sufficient follow-up duration for identifying 
parameters as a cause of death in our study. Immunosuppressive agents, especially 
calcineurin inhibitors, can cause acute on chronic kidney injury, but precise information on 
those medications was not available in the UNOS database. These constraints limited our 
ability to evaluate the cause of renal non-recovery and the exact cause of mortality. Further 
studies using prospectively collected data should be performed.
In the current study, renal failure was more common in patients with ALD and NASH than 
in those with hepatitis C. This higher prevalence can be due to several reasons: first, recent 
studies using UNOS database have shown that patients with ALD have more severe liver 
dysfunction and higher prevalence of bacterial peritonitis than those with hepatitis C (1, 3). 
The severity of liver disease has been reported to be closely associated with the development 
of renal failure in cirrhotic patients (23, 24), which can partially explain the high prevalence 
of renal failure in ALD patients undergoing LT. Second, patients with NASH are more likely 
to have diabetes, which is commonly associated with intrinsic renal disease and/or 
progressive CKD. These co-morbid conditions may explain the higher prevalence of renal 
failure in patients with NASH. Patients with diabetes also have worse post-LT outcomes 
(25). AKI is associated with high mortality in patients with advanced cirrhosis (26, 27). Not 
surprisingly, renal failure also has a negative impact on the survival of patients undergoing 
LT (9–11, 16, 28). Consistent with previous studies, our study shows that renal failure is 
associated with poor patient survival and graft survival in the overall series and in each liver 
disease group undergoing LT. Moreover, we analyzed survival impact of renal failure across 
MELD groups; it was only a predictive factor in 20–30 MELD group. Furthermore, survival 
analysis across MELD groups showed that MELD <20 group were less likely to survive than 
those with higher MELD score (Supplementary_Figure 1). Higher survival rate of patients 
with higher MELD score can be explained, at least in part, by the increase in number of 
combined liver-kidney transplants (12.44% vs 0.97%, p <0.0001) in these patients. We are 
conducting a separate study to address the impact of combined transplant in this cohort.
The major finding in this study is that the impact of renal failure is less marked in patients 
with ALD than in patients with NASH or hepatitis C. The exact mechanisms by which 
different etiologies of liver disease impact survival could not be clearly determined from the 
available UNOS data. One potential hypothesis is that renal failure in patients with ALD is 
more relevant to hepatic dysfunction, and that renal recovery is more common in ALD than 
non-ALD patients. According to recent reports, HRS is more common in ALD (5), and a 
considerable portion of HRS patients experience renal recovery after LT (10, 17). 
Furthermore, renal failure in patients with ALD can be due to IgA nephropathy, which is 
known to be partially reversible after abstinence (15).
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Patients with NASH commonly have parenchymal kidney disease, such as diabetic 
nephropathy. The presence of CKD in patients with NASH may have contributed to the 
higher percentage non-recovery of renal failure after LT (12). Recent reports showed that 
diabetes, either alone or co-morbid with obesity, is associated with significantly greater post-
transplant mortality (22, 25). In the current study, we found that diabetes was more common 
in non-ALD patients with renal failure than ALD patients with renal failure. Renal failure in 
combination with NASH may result in a more aggressive natural history leading to increased 
risk of other health outcomes including cardiovascular events and ultimately lower overall 
survival, (21). Future studies should prospectively evaluate the factors associated with 
outcome in patients with NASH and renal failure.
Patients with HCV infection can have concomitant CKD. Indeed, a recent investigation 
showed a higher prevalence of CKD and shorter kidney survival in patients with chronic 
HCV infection (29). In the present study, we could not use detailed information on the cause 
of renal dysfunction in patients with HCV infection, however, the possibility of concomitant 
CKD can partially explain the poor outcome in renal failure of patients with HCV infection.
Predicting the natural course of renal dysfunction following LT can help improve the 
selection of patients for LT versus combined liver-kidney transplant. AKI at the time of 
transplant due to HRS is expected to largely resolve whereas acute tubular necrosis, when 
severe, may transition directly to CKD or end-stage renal disease and necessitate a 
concomitant liver-kidney transplant. Previous studies suggested that the duration of pre-
transplant renal dysfunction has a negative impact on post-transplant renal function outcome 
(28, 30). Current guidelines recommend that a dialysis period longer than 8 weeks is an 
indication for combined liver-kidney transplantation in patients with cirrhosis and HRS (31). 
Based on the results of the current study, renal failure has a more negative impact on patient 
survival in patients with NASH undergoing LT, and these patients could benefit more from 
combined liver-kidney transplantation. However, more research is required to clarify this 
question.
In conclusion, our study shows that renal failure is associated with poor post-LT outcome, 
and the impact of renal failure on patient and graft survival is less marked in patients with 
ALD. These results may assist in identifying patients at risk of progressive renal disease, and 
identifying patients amenable to specific therapies while on the transplant wait list. 
Biomarker development for predicting renal non-recovery would be valuable in predicting 
risk for progressive CKD after LT.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
ALD alcoholic liver disease
AKI acute kidney injury
CKD chronic kidney injury
HR hazard ratio
HCV hepatitis C virus
HRS hepatorenal syndrome
LT liver transplantation
MELD model for end-stage liver disease
NASH non-alcoholic steatohepatitis
OPTN Organ Procurement and Transplantation Network
SBP Spontaneous Bacterial Peritonitis
UNOS United Network for Organ Sharing
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KEY POINTS
• Renal failure before liver transplantation is more frequent in 
transplanted patients with alcoholic and non-alcoholic fatty liver 
diseases compared to hepatitis C patients.
• The development of renal failure before liver transplantation is an 
independent predictor of poor survival in all patients with liver 
transplantation.
• The impact of pre-transplant renal failure on long-term survival is less 
marked in patients with alcoholic liver disease than in those with other 
etiologies.
• Further studies should investigate strategies to prevent the development 
of renal failure in patients with nonalcoholic fatty liver and hepatitis C 
who will undergo liver transplantation.
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Figure 1. 
Impact of renal failure on graft survival according to the etiology of the underlying liver 
disease. A) Overall series, B) Alcoholic liver disease (ALD), C) Non-alcoholic 
steatohepatitis (NASH), and D) Hepatitis C virus (HCV).
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Figure 2. 
Impact of renal failure on patient survival according to the etiology of the underlying liver 
disease. A) Overall series, B) Alcoholic liver disease (ALD), C) Non-alcoholic 
steatohepatitis (NASH), and D) Hepatitis C virus (HCV).
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Figure 3. 
Comparison of survival between renal failure patients with or without alcoholic liver disease. 
A) Patient survival, B) Graft survival.
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Table 2
Whole cohort outcomes according to etiology of liver disease.
Died Graft failure
ALD 1,693 2,007
NASH 628 736
Hepatitis C 4,594 5,509
ALD, alcoholic liver disease; NASH, nonalcoholic steatohepatitis.
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Table 3
Multivariate analysis of parameters predicting patient survival after liver transplantation in the whole series 
(n=24,798).
Variables Univariate P-value Hazard Ratio Multivariate P-value Hazard Ratio
Female gender <0.0001 1.123 <0.0001 1.190
Recipient age <0.0001 1.016 0.1530 1.003
Black race <0.0001 1.512 <0.0001 1.360
Donor age <0.0001 1.012 <0.0001 1.013
Body mass index <0.0001 0.990 <0.0001 0.984
Creatinine at transplant <0.0001 1.084 0.2413 0.979
Dialysis treatment <0.0001 1.449 0.1198 1.114
Renal failure <0.0001 1.466 0.0067 1.200
Renal recovery <0.0001 2.829 <0.0001 2.648
Combined liver-kidney transplant <0.0001 1.221 0.9235 1.007
Diabetes <0.0001 1.298 0.2405 1.054
Ascites at transplant <0.0001 1.143 0.2448 1.042
SBP at registration 0.0354 1.091 0.2891 1.063
Encephalopathy at transplant <0.0001 1.315 0.0538 1.104
Total bilirubin at transplant <0.0001 1.007 0.6753 1.001
MELD score <0.0001 1.008 0.0007 0.991
Anti-hepatitis B core antibody <0.0001 1.154 0.0003 1.142
Ventilator support <0.0001 1.968 0.0090 1.245
Portal vein thrombosis 0.0003 0.846 0.3354 0.936
Previous liver transplant <0.0001 1.923 <0.0001 1.562
Donor type (cadaver) <0.0001 1.336 0.6468 1.090
Whole liver transplant <0.0001 1.315 0.7808 1.045
Cold ischemic time <0.0001 1.014 0.0989 1.007
MELD, model for end-stage liver disease; SBP, Spontaneous Bacterial Peritonitis.
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Table 4
Impact of renal failure before liver transplant (LT) on patient survival and graft survival after LT by disease 
etiology*.
Comparison for patient survival (hazard ratio) p-value Comparison for graft survival (hazard ratio) p-value
ALD (1.314) vs. Hepatitis C (1.521) 0.0224 ALD (1.231) vs. Hepatitis C (1.392) 0.0482
ALD (1.314) vs. NASH (1.732) 0.0067 ALD (1.231) vs. NASH (1.499) 0.0417
NASH (1.732) vs. Hepatitis C (1.521) 0.1583 NASH (1.499) vs. Hepatitis C (1.392) 0.3732
ALD, alcoholic liver disease; NASH, nonalcoholic steatohepatitis.
*
This analysis does not include patients with previous LT.
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Table 5
Prevalence of clinical and laboratory parameters in patients with either ALD or non-ALD and renal failure at 
the time of liver transplant.
Parameters ALD (n=1,610) Non-ALD (n=3,203) p-value
Female gender 22.30% 33.37% <0.0001
Recipient Age 53.40 ± 8.97 54.84 ± 7.62 <0.0001
Black race 4.10% 13.92% <0.0001
Body mass index 27.90 ± 5.76 29.02 ± 6.07 0.0155
Creatinine at transplant 3.43 ± 1.73 3.74 ± 2.04 <0.0001
Dialysis treatment 62.55% 58.35% 0.0051
Creatinine at discharge 1.77 ± 1.25 1.86 ± 1.32 0.1411
Creatinine at last follow up 1.85 ± 1.44 1.91 ± 1.51 0.0594
Renal recovery 58.73% 56.30% 0.1444
Combined liver-kidney transplant 31.18% 31.47% 0.8377
Diabetes 22.73% 35.47% <0.0001
Hypertension 20.48% 25.59% 0.0611
Ascites at transplant 57.14% 54.45% 0.0761
SBP at registration 15.59% 11.43% <0.0001
Encephalopathy at transplant 24.20% 21.27% 0.0218
Malignancy at transplant* 0.63% 2.04% 0.0002
MELD score 29.27 ± 9.34 24.78 ± 10.01 0.0018
Hepatitis B surface antigen 1.61% 1.72% 0.8006
Anti-hepatitis B core antibody 6.79% 26.90% <0.0001
Ventilator support 12.48% 10.74% 0.0715
Portal vein thrombosis 6.75% 8.31% 0.0598
ABO mismatching 8.45% 8.93% 0.5770
Whole liver transplant 1.24% 1.59% 0.3419
Cold ischemic time 6.97 ± 3.09 7.06 ± 3.74 <0.0001
Warm ischemic time 40.76 ± 23.90 41.66± 19.46 <0.0001
Acute rejection episode 5.61% 5.10% 0.4856
Renal failure as cause of death 3.09% 2.61% 0.6112
Cardiovascular cause of death 17.56% 15.30% 0.2587
ALD, alcoholic liver disease; MELD, model for end-stage liver disease. SBP, Spontaneous Bacterial Peritonitis.
*
It refers to hepatocellular carcinoma. This analysis excluded those patients with a previous liver transplant.
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